1
|
Jaeger A, Gambheer SMM, Sun X, Chernyakov D, Skorobohatko O, Mack T, Kissel S, Pfeifer D, Zeiser R, Fisch P, Andrieux G, Bräuer-Hartmann D, Bauer M, Schulze S, Follo M, Boerries M, von Bubnoff N, Miething C, Hidalgo JV, Klein C, Weber T, Wickenhauser C, Binder M, Dierks C. Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood 2023; 141:2824-2840. [PMID: 36696631 DOI: 10.1182/blood.2022015653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Revised: 01/05/2023] [Accepted: 01/15/2023] [Indexed: 01/26/2023] Open
Abstract
Peripheral T-cell lymphomas (PTCLs), especially angioimmunoblastic and follicular TCLs, have a dismal prognosis because of the lack of efficient therapies, and patients' symptoms are often dominated by an inflammatory phenotype, including fever, night sweats, weight loss, and skin rash. In this study, we investigated the role of inflammatory granulocytes and activated cytokine signaling on T-cell follicular helper-type PTCL (TFH-PTCL) disease progression and symptoms. We showed that ITK-SYK-driven murine PTCLs and primary human TFH-PTCL xenografts both induced inflammation in mice, including murine neutrophil expansion and massive cytokine release. Granulocyte/lymphoma interactions were mediated by positive autoregulatory cytokine loops involving interferon gamma (CD4+ malignant T cells) and interleukin 6 (IL-6; activated granulocytes), ultimately inducing broad JAK activation (JAK1/2/3 and TYK2) in both cell types. Inflammatory granulocyte depletion via antibodies (Ly6G), genetic granulocyte depletion (LyzM-Cre/MCL1flox/flox), or IL-6 deletion within microenvironmental cells blocked inflammatory symptoms, reduced lymphoma infiltration, and enhanced mouse survival. Furthermore, unselective JAK inhibitors (ruxolitinib) inhibited both TCL progression and granulocyte activation in various PTCL mouse models. Our results support the important role of granulocyte-driven inflammation, cytokine-induced granulocyte/CD4+ TCL interactions, and an intact JAK/STAT signaling pathway for TFH-PTCL development and also support broad JAK inhibition as an effective treatment strategy in early disease stages.
Collapse
Affiliation(s)
- Amelie Jaeger
- Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Sudheer Madan Mohan Gambheer
- Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Xiaoyang Sun
- Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Dmitry Chernyakov
- Hematology/Oncology and Stemcell transplantation, University of Halle-Wittenberg, Halle, Germany
| | - Oleksandra Skorobohatko
- Hematology/Oncology and Stemcell transplantation, University of Halle-Wittenberg, Halle, Germany
| | - Thomas Mack
- Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Sandra Kissel
- Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Dietmar Pfeifer
- Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Robert Zeiser
- Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Paul Fisch
- Department of Pathology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Geoffroy Andrieux
- Institute of Medical Bioinformatics and Systems Medicine, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Daniela Bräuer-Hartmann
- Hematology/Oncology and Stemcell transplantation, University of Halle-Wittenberg, Halle, Germany
| | - Marcus Bauer
- Institute of pathology, University Hospital Halle, Halle, Germany
| | - Susann Schulze
- Krukenberg Cancer Center Halle, University Hospital Halle, Halle, Germany
| | - Marie Follo
- Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Melanie Boerries
- Institute of Medical Bioinformatics and Systems Medicine, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
- German Cancer Consortium, Partner Site Freiburg, Freiburg, Germany
- German Cancer Research Center, Heidelberg, Germany
| | - Nikolas von Bubnoff
- Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Cornelius Miething
- Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Jose Villacorta Hidalgo
- Department of Pathology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Claudius Klein
- Department of Hematology and Oncology, Freiburg University Medical Center, Albert Ludwig University of Freiburg, Freiburg, Germany
| | - Thomas Weber
- Hematology/Oncology and Stemcell transplantation, University of Halle-Wittenberg, Halle, Germany
| | | | - Mascha Binder
- Hematology/Oncology and Stemcell transplantation, University of Halle-Wittenberg, Halle, Germany
| | - Christine Dierks
- Hematology/Oncology and Stemcell transplantation, University of Halle-Wittenberg, Halle, Germany
| |
Collapse
|